Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy.

导出 LinkOut

翻译打印收藏纠错

第一作者： Kazuki,Maesaka

第一单位： Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

作者： Kazuki,Maesaka ^[1] ; Ryotaro,Sakamori ^[1] ; Ryoko,Yamada ^[1] ; Yuki,Tahata ^[1] ; Yasuharu,Imai ^[2] ; Kazuyoshi,Ohkawa ^[3] ; Masanori,Miyazaki ^[4] ; Eiji,Mita ^[5] ; Toshifumi,Ito ^[6] ; Hideki,Hagiwara ^[7] ; Takayuki,Yakushijin ^[8] ; Takahiro,Kodama ^[1] ; Hayato,Hikita ^[1] ; Tomohide,Tatsumi ^[1] ; Tetsuo,Takehara ^[1]

作者单位： Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan. ^[1] Department of Gastroenterology and Hepatology, Ikeda Municipal Hospital, Ikeda, Osaka, Japan. ^[2] Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan. ^[3] Department of Gastroenterology and Hepatology, Osaka Police Hospital, Osaka, Osaka, Japan. ^[4] Department of Gastroenterology and Hepatology, National Hospital Organization Osaka National Hospital, Osaka, Osaka, Japan. ^[5] Department of Gastroenterology and Hepatology, Japan Community Healthcare Organization, Osaka Hospital, Osaka, Osaka, Japan. ^[6] Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Hyogo, Japan. ^[7] Department of Gastroenterology and Hepatology, Osaka General Medical Center, Osaka, Osaka, Japan. ^[8]

关键词 atezolizumab plus bevacizumab hepatocellular carcinoma hyperprogressive disease

DOI 10.1111/hepr.13741

PMID 34918428

发布时间 2022-05-18

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交